comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - European lung cancer conference - Page 1 : comparemela.com
Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
Summit Therapeutics Inc. reports earnings inline with expectations. Reported EPS is $-0.06 EPS, expectations were $-0.06.
Canada
Japan
China
United-states
Texas
Chinese
America
American
Bob-duggan
Allen-yang
Brad-canino
Bradley-canino
Combination Chemotherapy and Immunotherapy for Advanced NSCLC
Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.
Small-cell-lung-cancer
Felcc
European-lung-cancer-conference
Nsclc
Lung-cancer
Non-small-cell-lung-cancer
Immunotherapy
Immunotherapy-nsclc
Advanced-nsclc-pd-l1-testing
Pd-l1-testing
Assays
The Evolution of Chemoimmunotherapy in Advanced NSCLC
Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.
Small-cell-lung-cancer
Felcc
European-lung-cancer-conference
Nsclc
Lung-cancer
Non-small-cell-lung-cancer
Immunotherapy
Immunotherapy-nsclc
Advanced-nsclc-pd-l1-testing
Pd-l1-testing
Assays
Subgrouping Patients with Advanced NSCLC for Tailored Treatment
The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.
Small-cell-lung-cancer
Felcc
European-lung-cancer-conference
Nsclc
Lung-cancer
Non-small-cell-lung-cancer
Immunotherapy
Immunotherapy-nsclc
Advanced-nsclc-pd-l1-testing
Pd-l1-testing
Assays
Overview of PD-L1 Testing in Advanced NSCLC
Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.
Marina-garassino
Small-cell-lung-cancer
Felcc
European-lung-cancer-conference
Nsclc
Lung-cancer
Non-small-cell-lung-cancer
Immunotherapy
Immunotherapy-nsclc
Advanced-nsclc-pd-l1-testing
Pd-l1-testing
vimarsana © 2020. All Rights Reserved.